Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy

Authors, Journal, Affiliations, Type, DOI

• Authors: Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL, et al. (International Takotsubo Registry Investigators)
• Journal: New England Journal of Medicine
• Affiliations: University Hospital Zurich (lead); 25 collaborating cardiovascular centres across 9 countries (Austria, Finland, France, Germany, Italy, Poland, Switzerland, UK, USA)
• Type: Multicentre prospective-plus-retrospective registry; age- and sex-matched comparison with ACS cohort
• DOI: https://doi.org/10.1056/NEJMoa1406761
• Funded by: Mach-Gaensslen Foundation and others; ClinicalTrials.gov NCT01947621

Overview

The International Takotsubo Registry enrolled 1,750 patients from 26 centres across 9 countries (1998–2014) to characterise the clinical features, prognostic predictors, and long-term outcomes of takotsubo cardiomyopathy (TTS). Key findings overturned several prevailing assumptions: physical triggers (36.0%) outnumbered emotional triggers (27.7%); in-hospital serious complication rates equalled those of ACS (21.8%); and beta-blockers — widely used empirically — conferred no survival benefit, while ACEi/ARB did. Long-term mortality (5.6%/year) and MACCE (9.9%/year) were substantially higher than previously appreciated.

Keywords

Takotsubo cardiomyopathy, stress cardiomyopathy, apical ballooning, brain–heart axis, acute heart failure, catecholamine, neuropsychiatric disorders, registry

Key Takeaways

Epidemiology and Baseline Features

• n=1,750; 89.8% women; mean age 66.8 years; enrolled from 26 centres across 9 countries
• Triggers: physical 36.0% > emotional 27.7%; no evident trigger 28.5%; physical triggers outnumber emotional triggers — contradicts historical impression
• Neuropsychiatric comorbidity: 55.8% of TTS patients vs 25.7% ACS (P<0.001) — one of the most striking differences from ACS
• Coexisting CAD present in 15.3% — does not exclude TTS diagnosis (Mayo Clinic criteria allow exception)

Morphology

• Apical pattern: 81.7% (classic octopus-pot morphology)
• Midventricular: 14.6%
• Basal: 2.2%
• Focal: 1.5%

ECG and Biomarkers

• Troponin elevated in 87% — but rises only ×1.8× upper limit of normal vs ×6 in ACS; magnitude distinction useful diagnostically
• CK elevation absent (clinically useful negative)
• BNP/NT-proBNP ×5.9× ULN — disproportionately elevated relative to troponin
• QTc prolongation substantial (specific value not reported in abstract; clinically significant)
• ST depression only 8.3% of TTS vs 31.1% of ACS — marked contrast

Haemodynamics and Imaging

• Mean LVEF 40.7±11.2% in TTS vs 51.5±12.3% in ACS (P<0.001)
• LVEDP >11 mmHg in 93% — acute diastolic dysfunction universal

In-Hospital Complications

• Serious in-hospital complications: 21.8% in TTS vs ACS-equivalent rate (P=0.93) — TTS is not a benign condition
• VT: 3.0%; LV thrombus: 1.3%; free wall rupture: 0.2%
• Independent predictors of in-hospital complications (multivariable):
  • Higher risk: physical trigger, acute neurological or psychiatric disease, troponin >10× ULN, LVEF <45% on admission
  • Lower risk: older age, emotional trigger

Short-Term Outcomes

• 30-day MACCE: 7.1% overall; men 13.7% vs women 6.3% — men have nearly double the short-term event rate

Long-Term Outcomes

• Death: 5.6%/year
• MACCE: 9.9%/year
• Recurrence: 1.8%/year
• Stroke/TIA: 1.7%/year
• Sex disparity: Men: death 12.9%/yr vs women 5.0%/yr (P<0.001) — men have strikingly worse prognosis despite smaller proportion of patients

Treatment Effects (Propensity Analysis)

• ACEi/ARB: Improved 1-year survival (P=0.001 after propensity matching) — only medication class with survival signal
• Beta-blockers: NO survival benefit (P=0.72 after propensity matching)
  • 32.5% of patients were already on beta-blockers when TTS occurred
  • 29 of 57 recurrences occurred while on beta-blockers
  • Catecholamine-excess hypothesis for beta-blocker benefit not supported by outcome data

Limitations of the Document

• Registry design: Non-randomised; confounding in treatment comparisons despite propensity matching (unmeasured confounders possible)
• ACS comparison subgroup: Only 455/1750 patients contributed to the ACS comparison (five dedicated centres only); may not represent the full registry population
• Temporal heterogeneity: Cases enrolled 1998–2014 — management practices evolved substantially over this period
• Trigger classification: Categorisation as emotional/physical relies on retrospective reporting and may misclassify
• No randomised treatment data: ACEi/ARB and beta-blocker findings are observational; hypothesis-generating only
• Predominantly European cohort: Limited generalisability to Asian populations where TTS was first described and may have different phenotype

Key Concepts Mentioned

• concepts/Brain-Heart-Axis — neuropsychiatric comorbidity and catecholamine excess as central pathophysiological hypothesis
• concepts/Acute-Heart-Failure — TTS defined as an acute HF syndrome in the conclusions

Key Entities Mentioned

• entities/Takotsubo — primary subject; clinical features, predictors, and outcomes from largest registry
• entities/Heart-Failure — TTS characterised as acute HF syndrome; in-hospital complications equal to ACS

Wiki Pages Updated

• wiki/sources/takotsubo-nejm-2015.md — created (this file)
• wiki/entities/Takotsubo.md — created (new entity page)
• wiki/entities/Heart-Failure.md — updated (TTS section added)
• wiki/sourceindex.md — updated
• wiki/wikiindex.md — updated